

## For Health Professionals Who Care for Cancer Patients

### Inside This Issue:

#### Editor's Choice

**BRAVPEM, BRAVPEM6:** Pembrolizumab for Triple-Negative Breast Cancer

#### Cancer Drug Manual®

**New:** Mogamulizumab **Revised:** Apalutamide, Durvalumab, Lenvatinib; Chemotherapy and Stability Chart: Mogamulizumab, Teclistamab; Hepatitis prophylaxis: Acalabrutinib, Bosutinib, Daratumumab, Dasatinib, Everolimus, Ibrutinib, Imatinib, Melphalan, Tocilizumab, Zanubrutinib **Acknowledgements**

#### Continuing Education

##### Family Practice Oncology Network

Continuing Medical Education: Colorectal Cancer Current Screening Recommendations and Follow-Up Care

#### Benefit Drug List

**New:** BRAVPEM, BRAVPEM6

#### NEW Protocols, PPPOs and Patient Handouts

**BR** BRAVPEM, BRAVPEM6

#### REVISED Protocols, PPPOs and Patient Handouts

**BR** UBRAJOLA, BRAJPEM, BRAJPN, BRAJPNCT, BRAJPNT, BRAVABR, BRAVPGC, BRAVPP, BRAVPPN, BRAVSG, BRLACPNAC, BRLACPNACG, BRLACTWAC, BRLACTWACG **GI** GIPGEMABR **LK** ULKAMLAVEN

#### Resources and Contact Information

## Editor's Choice

### New Programs

Effective 01 January 2024, the BC Cancer Provincial Systemic Therapy Program has approved the following new treatment programs. The full details of these programs can be found on the BC Cancer website in the [Chemotherapy Protocols](#) section.

#### Breast

**Pembrolizumab for Triple-Negative Breast Cancer (BRAVPEM, BRAVPEM6)** — The BC Cancer Breast Tumour Group is introducing two pembrolizumab protocols for patients who have completed or discontinued chemotherapy portion of BRAVPPN, BRAVPP, or BRAVPGC protocols. These protocols are used for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) and PDL-1 combined positive score > 10. For more details, see the [June 2023](#) issue of Systemic Therapy Update.

All documents are available in the [Cancer Drug Manual<sup>®</sup>](#) on the BC Cancer website.

### New Documents

Note that the following drug is not a BC Cancer Benefit Drug. The corresponding Interim Monograph and Patient Handout are made available for reference only.

The **Mogamulizumab Interim Monograph** has been expanded and a **Patient Handout** has been developed. Expert review was provided by Dr. Kerry Savage (medical oncologist, BC Cancer Lymphoma Tumour Group) and Megan Darbyshire (tumour group pharmacist, BC Cancer Provincial Pharmacy). All monograph sections have been reviewed and updated. The following sections have been added or expanded: *Pharmacokinetics, Special Precautions, Side Effects, Interactions, and Dosage Guidelines*. **Mogamulizumab** is a humanized IgG1κ monoclonal antibody which selectively binds to CC chemokine receptor 4 (CCR4). Mogamulizumab is used in the treatment of cutaneous T-cell lymphoma. Usual dose is 1 mg/kg IV given in a 28 day cycle. For cycle 1, mogamulizumab is given on days 1, 8, 15, and 22. For cycle 2 and subsequent cycles, mogamulizumab is given on days 1 and 15.

Highlights from these documents include:

- **infusion reactions** may occur; premedication is administered prior to the first mogamulizumab infusion in all patients
- **rash** is common and presentations may vary; skin biopsy may be required to distinguish rash from disease progression
- fatal **autoimmune complications** have occurred; use caution in patients with history of autoimmune disease

**Mogamulizumab** has been re-evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

### Revised Documents

#### Apalutamide Monograph

*Supply and Storage*: added new 240 mg tablet

*Supply and Storage (Additional information)*: added preparation instructions for alternative methods of administration (for patients who have trouble swallowing whole tablets)

#### Durvalumab Chemotherapy Preparation and Stability Chart

*Product Stability* column: updated with extended fridge stability

#### Lenvatinib Monograph and Patient Handout

*Cautions*: added osteonecrosis of the jaw and warnings about hepatic impairment to bullets

*Special Populations*: added hepatic encephalopathy to list of side effects more likely to occur in patients over 75 years of age

*Side Effects (table)*: updated emetogenic potential to align with BC Cancer protocols; updated incidence of vomiting; added impaired wound healing and osteonecrosis of the jaw

*Dosage Guidelines*: added new protocols GILEN, GOENDAVPL, GOENDAVPL6, GUAVPEML, GUAVPEML6, and HNOTLEN and updated dosage in hepatic failure

## Cancer Drug Manual<sup>©</sup>

*Patient Handout:* updated current template language throughout; updated nausea and diarrhea (*Side Effects table*) as per revised template; added osteonecrosis of the jaw to the *Side Effects table*

### **Mogamulizumab Chemotherapy Preparation and Stability Chart**

*Chemotherapy Preparation and Stability Chart:* added marketed supply and deleted SAP supply

### **Teclistamab Interim Monograph and Chemotherapy Preparation and Stability Chart**

*Supply and Storage:* deleted SAP supply

*Chemotherapy Preparation and Stability Chart:* added marketed supply and deleted SAP supply

### **Hepatitis B Prophylaxis has been updated in the following monographs:**

Acalabrutinib  
Bosutinib  
Daratumumab  
Dasatinib  
Everolimus  
Ibrutinib  
Imatinib  
Melphalan  
Tocilizumab  
Zanubrutinib

## CDM Acknowledgements

The Cancer Drug Manual Editor, Nadine Badry (BC Cancer – Victoria), and CDM Writer, Amy Lim (BC Cancer – Abbotsford), would like to acknowledge the contributions of the CDM Editorial Review Board and expert reviewers for the year 2023. Thank you for your ongoing support of the CDM and for generously sharing your time and expertise throughout the year.

### **Editorial Board**

#### ***Physicians***

Angela Chan, BC Cancer – Surrey  
Mario Ho, BC Cancer – Prince George  
Jean-Michel Lavoie, BC Cancer –  
Victoria

#### ***Nurses***

Megan Crosby, BC Cancer – Prince  
George  
Michelle Lafreniere, BC Cancer –  
Victoria

#### ***Pharmacists***

Alysha Bharmal, BC Cancer – Surrey  
Jennifer Kendrick, BC Children's Hospital  
Jennifer Suess, BC Cancer – Abbotsford

### **Expert Reviewers**

#### ***Physicians***

Teresa Chan, BC Cancer – Surrey  
Nicole Chau, BC Cancer – Vancouver  
Donna Forrest, BC Cancer – Vancouver  
Nathalie Levasseur, BC Cancer – Vancouver  
Kerry Savage, BC Cancer – Vancouver  
Sophie Sun, BC Cancer – Vancouver  
Christopher Venner, BC Cancer – Vancouver  
Diego Villa, BC Cancer - Vancouver  
Alison Wepler, BC Cancer - Vancouver

#### ***Pharmacists***

Rachel Kim, BC Cancer – Provincial Pharmacy  
Megan Darbyshire, BC Cancer – Provincial Pharmacy

## Continuing Education

### Family Practice Oncology Network Continuing Medical Education

The Family Practice Oncology Network (FPON) is pleased to announce a complimentary accredited webinar session on 'Colorectal Cancer Current Screening Recommendations and Follow-Up Care' on **Thursday, 18 January, from 8 am to 9 am**, as part of the ongoing Complimentary Accredited Webinar Series. This session will cover:

- Risk factors for the development of colon cancer and their impact on screening strategy;
- Current colon screening and surveillance recommendations;
- Follow-up recommendations post-colorectal cancer treatment.

This session is offered at **no charge** and is accredited at up to 1.0 Mainpro+ credits.

For more information and links to registration, visit the FPON Continuing Medical Education site at [fpon.ca](http://fpon.ca) or <https://ubccpd.ca/learn/learning-activities/course?eventtemplate=661-fpon-webinar-colorectal-cancer-current-screening-recommendations-and-followup-care>

## Benefit Drug List

### New Programs

Effective 01 January 2024, the following new treatment programs have been added to the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Treatment of Metastatic Breast Cancer using <b>Pembrolizumab</b>	BRAVPEM	Class I
Treatment of Metastatic Breast Cancer using 6-Weekly <b>Pembrolizumab</b>	BRAVPEM6	Class I

## List of Revised Protocols, Pre-Printed Orders and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

### NEW Protocols, PPPOs and Patient Handouts (*new documents checked* )

Code	Protocol Title	Protocol	PPPO	Handout
BRAVPEM	Treatment of Metastatic Breast Cancer using Pembrolizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--
BRAVPEM6	Treatment of Metastatic Breast Cancer using 6-Weekly Pembrolizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--

### REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
<b>BR   Breast</b>				
UBRAJOLA	Treatment of BRCA-Mutated High-Risk Early Breast Cancer using Olaparib	<i>Eligibility &amp; tests updated</i>	--	--
BRAJPEM	Adjuvant Treatment of Resected Triple Negative Breast Cancer using Pembrolizumab	<i>Eligibility &amp; premedications updated</i>	<i>Tests &amp; language in return labs updated</i>	--
BRAJPN	Alternative Adjuvant Therapy for Breast Cancer using PACLitaxel NAB (ABRAXANE)	<i>Bilirubin, ALT, creatinine added to routine labs, physician and phone numbers updated</i>	<i>Bilirubin, ALT, creatinine added to routine labs; Bilirubin, ALT added to Pre-chemo metrics</i>	--
BRAJPNCT	Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using PACLitaxel NAB (ABRAXANE), CARBOplatin and Trastuzumab	<i>Bilirubin, ALT added to routine labs, physician and phone numbers updated</i>	<i>Bilirubin, ALT added to routine labs and Pre-chemo metrics</i>	--
BRAJPNT	Alternative Adjuvant Therapy for Breast Cancer using PACLitaxel NAB (ABRAXANE) and Trastuzumab	<i>Bilirubin, ALT, creatinine added to routine labs, physician and phone numbers updated</i>	<i>Bilirubin, ALT, creatinine added to routine labs; Bilirubin, ALT added to Pre-chemo metrics</i>	--

## REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Code	Protocol Title	Protocol	PPPO	Handout
<b>BRAVABR</b>	Palliative Therapy for Metastatic Breast Cancer using PACLitaxel NAB (ABRAXANE)	<i>Bilirubin, ALT, creatinine added to routine labs, physician and phone numbers updated</i>	<i>Bilirubin, ALT, creatinine added to routine labs; Bilirubin, ALT added to Pre-chemo metrics</i>	--
<b>BRAVPGC</b>	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab, Gemcitabine, and CARBOplatin	<i>Eligibility, premedications &amp; treatment updated</i>	--	--
<b>BRAVPP</b>	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab with PACLitaxel	<i>Eligibility, premedications &amp; treatment updated</i>	--	--
<b>BRAVPPN</b>	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab and PACLitaxel NAB (ABRAXANE)	<i>Eligibility, premedications &amp; treatment updated</i>	--	--
<b>BRAVSG</b>	Palliative Therapy for Metastatic Triple Negative Breast Cancer using Sacituzumab Govitecan	<i>Eligibility &amp; tests updated</i>	--	--
<b>BRLACPNA</b>	Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	<i>Eligibility, tests, premedications &amp; dose modifications updated</i>	--	--
<b>BRLACPNA</b>	Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide	<i>Eligibility, tests, premedications &amp; dose modifications updated</i>	--	--
<b>BRLACTWAC</b>	NEOAdjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	<i>Title, eligibility &amp; tests updated</i>	--	--
<b>BRLACTWAC</b>	NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: Carboplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	<i>Eligibility &amp; tests updated</i>	--	--
<b>BRLAPNAC</b>	Alternative NEOAdjuvant Therapy for Locally Advanced Breast Cancer using PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	<i>Bilirubin, ALT, creatinine added to routine labs for paclitaxel NAB, physician and phone numbers updated</i>	<i>Bilirubin, ALT, creatinine added to routine labs cycles 1 to 4; Bilirubin, ALT added to Pre-chemo metrics for paclitaxel NAB</i>	--

## REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Code	Protocol Title	Protocol	PPPO	Handout
<b>BRLAPNACG</b>	Alternative NEOAdjuvant Therapy for Breast Cancer using Dose Dense Therapy: PACLitaxel NAB (ABRAXANE) followed by DOXOrubicin and Cyclophosphamide	<i>Bilirubin, ALT, creatinine added to routine labs for paclitaxel NAB, physician and phone numbers updated</i>	<i>Bilirubin, ALT, creatinine added to routine labs cycles 1 to 4; Bilirubin, ALT added to Pre-chemo metrics for paclitaxel NAB</i>	--
<b>BRPCTAC</b>	NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with CARBOplatin and Weekly PACLitaxel Followed by DOXOrubicin and Cyclophosphamide	<i>Eligibility &amp; tests updated</i>	--	--
<b>BRPCWTAC</b>	NEOAdjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly CARBOplatin and Weekly PACLitaxel, Followed by DOXOrubicin and Cyclophosphamide	<i>Eligibility &amp; tests updated</i>	--	--
<b>GI   Gastrointestinal</b>				
<b>GIPGEMABR</b>	First Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with PACLitaxel NAB (ABRAXANE) and Gemcitabine	--	<i>Pre-chemo metrics updated</i>	--
<b>LK   Leukemia</b>				
<b>ULKAMLAVEN</b>	Therapy of Acute Myeloid Leukemia using azaCITIDine and Venetoclax	<i>Remission clarified in Dose Modifications</i>	<i>Remission clarified, time of pre-metrics changed from 24 to 96 hours</i>	--

## Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: <a href="http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update">www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update</a>		
Systemic Therapy Update Editor	604-877-6000 x 672649	<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Oncology Drug Information	604-877-6275	<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
Cancer Drug Manual Editor	250-519-5500 x 693742	<a href="mailto:nbadry@bccancer.bc.ca">nbadry@bccancer.bc.ca</a>
Pharmacy Oncology Certification	250-712-3900 x 686820	<a href="mailto:rxchemocert@bccancer.bc.ca">rxchemocert@bccancer.bc.ca</a>
Nurse Educators	604-877-6000 x 672638	<a href="mailto:nursinged@bccancer.bc.ca">nursinged@bccancer.bc.ca</a>
CAP – Compassionate Access Program	604-877-6277	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a> fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a> fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 <a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Library Document Delivery	604-675-8002	<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Pharmacy Professional Practice	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
Professional Practice, Nursing	604-877-6000 x 672623	<a href="mailto:BCCancerPPNAdmin@ehcnet.phsa.ca">BCCancerPPNAdmin@ehcnet.phsa.ca</a>
Provincial Systemic Therapy Program	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: <a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>		

## Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Interim Editor)  
 Jeevan Dosanjh, RN, BScN  
 Alina Gerrie, MD, MPH, FRCPC

Samuel Hackett, RN, BScN, CON(C)  
 Alison Pow, BScPharm